Literature DB >> 23481618

Right ventricle to pulmonary artery conduit reoperations in patients with tetralogy of fallot or pulmonary atresia associated with ventricular septal defect.

Kevin Ong1, Robert Boone, Min Gao, Ron Carere, John Webb, Marla Kiess, Jasmine Grewal.   

Abstract

The short lifespan of right ventricle-to-pulmonary artery (RV-PA) conduits used in repairs of complex congenital heart defects makes future surgical replacement inevitable. Percutaneous pulmonary valve implantation (PPVI) now offers an attractive alternative to surgery in some patients. The objectives of this study were to examine the pattern of conduit reoperations, the factors affecting conduit longevity, and to discuss the role of PPVI in these patients. Forty-nine patients (mean age 27 ± 8 years) with pulmonary atresia or pulmonary stenosis with tetralogy of Fallot who underwent surgery for RV-PA conduits from September 1974 to October 2011 were reviewed. A total of 106 RV-PA conduits were implanted, 57 of which were replacements. Second, third, and fourth conduits were required during the follow-up period in 39, 16, and 2 patients, respectively. Freedom from reoperation at 10 years for the first, second, and third conduits was 50%, 74%, and 86%, respectively. Significant independent predictors of shorter conduit longevity included smaller conduit and conduit type (homograft and other vs Dacron). Furthermore, a significant proportion (32 of 57 [56%]) of conduit replacements took place from ages 9 to 18 years. There were 37 adults whose current existing conduits had not yet failed, with 73% (27 of 37) potentially suitable in the future for PPVI on the basis of conduit size of 16 to 27 mm. In conclusion, multiple RV-PA conduit revisions were required in patients who survived to adulthood, with many replacements taking place during adolescence. Most conduits in this adult cohort met size criteria for PPVI, thereby offering these patients a potential alternative to surgical intervention for conduit failure. Crown
Copyright © 2013. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23481618     DOI: 10.1016/j.amjcard.2013.01.337

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  7 in total

1.  Mid- to long-term outcomes of bovine jugular vein conduit implantation in Chinese children.

Authors:  Hui-Feng Zhang; Gang Chen; Ming Ye; Xian-Gang Yan; Qi-Lin Tao; Bing Jia
Journal:  J Thorac Dis       Date:  2017-05       Impact factor: 2.895

Review 2.  Role of CT in the Pre- and Postoperative Assessment of Conotruncal Anomalies.

Authors:  Parveen Kumar; Mona Bhatia
Journal:  Radiol Cardiothorac Imaging       Date:  2022-06-30

3.  Right ventricular outflow reconstruction with handmade valve conduit - A short experience from a developing country. Case series.

Authors:  Yasir Khan; Syed Shahabuddin; Muneer Amanullah
Journal:  Ann Med Surg (Lond)       Date:  2020-09-01

Review 4.  Transcatheter Pulmonary Valve Replacement: Current State of Art.

Authors:  Wail Alkashkari; Amani Alsubei; Ziyad M Hijazi
Journal:  Curr Cardiol Rep       Date:  2018-03-15       Impact factor: 2.931

5.  Percutaneous pulmonary valve implantation as an alternative to repeat open-heart surgery for patients with pulmonary outflow obstruction: a reality in Singapore.

Authors:  Shakeel Ahmed Quereshi; Swee Chye Quek; Lik Wui Edgar Tay; Wei Luen James Yip; Ting Ting Low; Chin Ling William Yip; Kok Fai William Kong; Tiong Cheng Yeo; Huay Cheem Tan
Journal:  Singapore Med J       Date:  2018-11-29       Impact factor: 1.858

Review 6.  Impact of Right-Sided-Catheter-Based Valve Implantation on Decision-Making in Congenital Heart Disease.

Authors:  Joanna Ghobrial; Jamil Aboulhosn
Journal:  Curr Cardiol Rep       Date:  2016-04       Impact factor: 2.931

7.  Current era outcomes of pulmonary atresia with ventricular septal defect: A single center cohort in Thailand.

Authors:  Kanthalas Lertsakulpiriya; Chodchanok Vijarnsorn; Prakul Chanthong; Paweena Chungsomprasong; Supaluck Kanjanauthai; Kritvikrom Durongpisitkul; Jarupim Soongswang; Thaworn Subtaweesin; Somchai Sriyoschati
Journal:  Sci Rep       Date:  2020-03-20       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.